Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311 22. S4.2-12. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347 57. S4.2-13. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and car- diovascular outcomes in patients with type 2 diabetes and cardio- vascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519 29. S4.2-14. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovas- cular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834 44. 4.3. High Blood Cholesterol S4.3-1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the man- agement of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082 1143. S4.3-2. Cholesterol Treatment Trialists (CTT) CollaborationBaigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S4.3-3. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181 92. S4.3-4. Cholesterol Treatment Trialists (CTT) CollaborationHerrington W, Emberson J, et al. Impact of renal function on the effects of LDL cho- lesterol lowering with statin-based regimens: a meta-analysis of indi- vidual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829 39. S4.3-5. Chou R, Dana T, Blazina I, et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force. Report No. 14-05206-EF-2. Rockville, MD: U.S. Agency for Healthcare Research and Quality, 2016. 